Abstract
Key content Surgical cytoreduction and platinum‐based chemotherapy are the mainstays of ovarian cancer treatment, but 70% of patients with advanced‐stage disease will relapse after responding to first‐line chemotherapy. Recent randomised controlled trials have shown significant improvement in progression‐free survival by adding maintenance therapy including either PARP inhibitors (PARPi), bevacizumab (VEGF‐A inhibitor), or both. Homologous recombination repair is a pathway to repair DNA breaks; homologous recombination deficiency (HRD) is encountered in approximately 50% of ovarian high‐grade serous cancers (HGSC). Patients with HRD tumours demonstrate better progression‐free survival outcomes with PARPi. HRD testing is now approved for patients with high‐grade ovarian cancers including HGSC. Learning objectives To understand available molecular testing in ovarian cancer in England and its implications for maintenance treatment strategies. Ethical issues Patient consent is required if testing involves germline BRCA1/2 mutation (gBRCA1/2mut) assessment. A positive BRCA1/2mut result might have implications for the patient and their family.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
